Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Finally, I don't like to talk smack about other traders plays. But, I do not like DM at all.
The NYSE does not screw around with delisting. And, I think their
Book Value is a ghost. I strongly recommend staying away.
I also own GEVO largely because I listened to Swampy's table pounding.
I typically do not like sub-$1 plays until after xmas, although I will trade them intraday.
Next week I will watch CH closely. The market doesn't like the socialist who may get elected there next week. But, I remember
making a nice trade on CUBA for a january effect play a few year ago.
This weekend I found another one I'm very high on. I will post it after I buy on Monday.
RNA
There is a binary event coming in January. GSK will decide whether to proceed with the compound they have been studying or move on to the next compound in the pipeline.
I like management. they are very conservative and non-promotional.
(Unlike their competition whose CEO I consider borderline incompetent)
Award winning pipeline
As I said, I like IPO-January Effect plays.
KBIO
I really like this chart.
They are cashed up with both an IPO & a secondary this past year
I like IPO January Effect plays. In the past they have performed well for me.
VICL
My favorite play right here right now. It's my largest position
and I'm still adding.
The negative is that a guy who bought 10% of the company last January is selling it off in 200,000 share chunks.
Paul Tudor Jones has been a recent buyer
Now that the Allovectin clusterfck is over, it's time to watch the market to find the rest of their pipeline again.
Propthink did a nice SA article. Here's hoping another pump comes soon.
KIOR
First, I have to say that I still don't like the chart. I have a partial position, but I'm willing to scale in
This is a great stock to own before investor presentations. They do a great job on roadshows.
They lured Khosa and Gates in with the their presentation.
The essence of the story is: Since folks don't read newspapers any more, we came up with a process to turn cheap wood pulp into fuel
A negative is that they are now gubment dependent and that's never a good place to be.
They project becoming cash flow positive in 2015.
OVRL
> Until the last couple days, this had the swampy flutter factor going.
> Just went thru an activist hedge fund mediated restructuring
> I love this volume pattern
> Above 1.23 it could break into the wayoutisphere
> Their BYOD offering should be popular, now that corporate america
wants to offload medical coverage & retirement benefits why not
facilitate using their own mobile devices too
ANTH is one of my favorites in here. I'm already in it. But, I'm willing to buy more
Here's what I like:
> relatively small float.
> catalyst Q1 2014 that my DD indicates will be a positive data readout.
> IHS may be forming here that counts up to around 4.
> Could be lightning in a bottle low float biotech on the right news or pump.
What I don't like:
> I don't know how much of their ATM financing has been used.
Unfortunately, This was a bounce trade gone bad for me. I had to hold it for a Q to get my money back and a little more. I'm not proud of this trade.
I don't have the cajones to trade like Dav123
Could be. I hadn't made that connection. Volume is still building.
ETRM has been very good to me. But, I'm no longer bullish on it.
I suspect a street.com mediated smackdown is coming.
Thanks for noticing Swampy. I never hold thru catalysts
Thanks Swampy.
Soon I'll be able to start front running ;-L
It's not an exciting play. Just tax selling overshoot followed by interested buyers. A competent CEO and a probability of incrementally better Q.
Also, I like plays that are not crowded by alpha chasers.
Sometimes volume analysis is more important than price analysis.I took a position in this one based on a close look at volume and noticing that most of the trades started going off at the ask
after that dip on the day I originally mentioned it.
Swampy, I'm going to drop a bucket of slop in here this weekend. Jaffecta is a December tradition for me.
Of course, I always have some level of worry I'm having my first red day in almost a month. But, I'll wait until tomorrow after noon before starting over.
I'm only in RSYS small right now. I'll be more interested when the daily looks like it's bottoming. Sellers and buyers are still exchanging rounds.
But I think that gap at 2.7X will get challenged before next earnings. Part of the reason I think that is that most of the drop today happened on a twenty-some thousand share sell and it's been almost all buying ever since.
I'm Scaling back into $RNA on the way down.
Two of my favorite January Effect plays are:
1. VICL Now, my largest position. I'm willing to add. I like the chart and it's pipeline is very good. It's a Seeking Alpha article away from spiking higher.
2. RSYS I like the CEO. Next Q will be an improvement.
I did start VICL today. It looks like its creating a bottom. But, I will add if it goes lower
Sorry for the delay. I just saw your message.
Technically, I love higher volume red hollow bodies. That gap looks like it has a very high probability of getting filled soon.
But, I stay away from holding this stock overnight. I've listened to a couple CCs and I think the CEO is a top shelf scumbag. I don't trust him with my money.
I still have half a position. RNA has so much room to run and ,possibly, a giant gap to fill. But, I will continue to trade a half position around until it feels like it has a bid.
Unfortunately, right now it seems like the only time there is predictable liquidity is during the first 15 minutes of each session.
I sold half RNA on early session strengh. IMO, it's too early in the tax loss selling season for it to reach your target. I don't like how it behaved on this mornings news.
Before you call this strong news, shouldn't you know how long to completion for this Phase IIB and be able to evaluate whether there is likelihood of priority review? Seems neutral at best to me.
I made it a full position, end of day. But, I'm not sure that was a disciplined buy. I think institutional sellers are mainly out now, leaving individuals who don't track their holdings on a daily basis until EOY advisor-mediated tax decisions.
It's trading thin now. And, I'm imagining there are folks like me waiting for short-lived selling spikes.
Let's hope GSK knows something about their pipeline that makes it a good deal for everyone at $8 - 10/ share.
This happened to me about 6 or 7 years ago when JNJ bought out a tax loss bottomfish I was holding in December. I woke up to a double. Enuf Fantasy, GLTA.
I took 1/2 position today. I'm willing to make it a double position. But, IPOs near the their lows do not typically do well during tax loss season. We'll see.
I've never used QuoteTracker, so please excuse my ignorance. Does your software have audible alerts?
TIA,
Dan
CNTF earnings next monday.
Nice risk reward here, considering company's cash position
It will be interesting to see if there were developments with their gaming console patents this past Q: http://seekingalpha.com/article/1719982-china-techfaith-could-benefit-from-the-new-free-trade-zone
It's always interesting when Sheehy is on the call.
Very wise.
There were no signs of accumulation before the spike; so, I would definitely not call that a good chart. Without more news, I suspect it will be a one day wonder for the longs.
I was short from Tuesday afternoon and covered yesterday. If this thing get's above 3.50 again on this questionable Lorem transaction, I would love to recycle that short.
If you haven't looked at the fundamentals of CYTX plus the sketchiness of that recently announced deal, you don't have enough eyes.
That thing is as over on that news as can possibly be.
I bought $REGI @ 13.15. I'll average down tomorrow if I get a chance.
GSAT might drum up some more enthusiasm for its shares on the conference call scheduled tomorrow. Here's some details: http://www.bloomberg.com/news/2013-11-04/globalstar-wins-fcc-review-on-use-of-satellite-airwaves.html?cmpid=yhoo ... I just got long
Speaking of Solars, this was a nice piece of digging:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=93643619
I like your theory on the mini-move. I loaded up on RSOL and MKTG yesterday. Both have earnings next week.
Today I bought ARTX @ 1.78. This is an earnings trade. I will not add.
My target is ~2.10. One of the keys to my trading outlook is to maintain modest expectations. Sometimes, my expectations are too modest.
Anyway, ARTX will report earnings on November 4. If stock picking is like judging a beauty contest, where most judges pick what others see as beautiful. Alotta cheap stock players find this stock attractive, especially into earnings.
So far, every call made on this thread has turned out.
TRIP was only a watch, not a call. I didn't like the way it traded on the day of the upgrade. So, I didn't buy it.
Today, I'll call ZLCS to follow through tomorrow. It's a Napodano "job"( and I mean that in at least a couple senses of the word) and he has big following. I'm already in and looking to add.
Sounds like a dirty business:
* The potential for unpaid VIP gambling debts.
* Increased competition.
* the unexpected death of the person who was going to introduce
their ipo to the Hong Kong Exchange.
* A competitor named Broken Tooth (lolz)
I did a search at Calvin Ayre for Macau VIP Gaming Rooms.
Here are the results:
http://calvinayre.com/search/?q=macao%20vip%20gaming%20rooms
I see this is the stock formerly known as AERL.
Hope this helps.
VEEV is due for an oversold, quiet period bounce. This is a high quality IPO carving out a new market. I'm beginning my scale in at 40 and will add 1/5 position at 39, 38, 37 & 36.
about 12 years ago, I used to hang out in a trading room run by an Ameritrade Challenge winner named Shadkin. He was a poker champion and short oriented. Any way, one of his favorite quant plays was to buy a stock if it was upgraded on the day of earnings or the day before. The win rate is very good, in part, because the analyst really looks like schmoe if he's wrong when highlighting such a near term earnings release.
TRIP was upgraded today and has earnings tomorrow. I will be stalking it.